Literature DB >> 30541724

Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group.

Erman Aytaç1, Fatih Aslan2, Bahattin Çicek1, Sibel Erdamar1, Bengi Gürses2, Koray Güven1, Okan Falay2, Tayfun Karahasanoğlu1, Fatih Selçukbiricik2, Uğur Selek2, Banu Atalar1, Emre Balık2, Nurdan Tözün1, İzzet Rozanes2, Ali Arıcan1, İsmail Hamzaoğlu1, Bilgi Baca1, Nil Molinas Mandel2, Murat Saruç1, Süha Göksel1, Gökhan Demir1, Fulya Ağaoğlu1, Cengiz Yakıcıer1, Uğur Özbek1, Volkan Özben1, Enis Özyar1, Ahmet Levent Güner1, Özlem Er1, Kerim Kaban2, Yasemin Bölükbaşı1, Dursun Buğra2, The İstanbul Group1.   

Abstract

The geographical location and differences in tumor biology significantly change the management of gastric cancer. The prevalence of gastric cancer ranks fifth and sixth among men and women, respectively, in Turkey. The international guidelines from the Eastern and Western countries fail to manage a considerable amount of inconclusive issues in the management of gastric cancer. The uncertainties lead to significant heterogeneities in clinical practice, lack of homogeneous data collection, and subsequently, diverse outcomes. The physicians who are professionally involved in the management of gastric cancer at two institutions in Istanbul, Turkey, organized a consensus meeting to address current problems and plan feasible, logical, measurable, and collective solutions in their clinical practice for this challenging disease. The evidence-based data and current guidelines were reviewed. The gray zones in the management of gastric cancer were determined in the first session of this consensus meeting. The second session was constructed to discuss, vote, and ratify the ultimate decisions. The identification of the T stage, the esophagogastric area, imaging algorithm for proper staging and follow-up, timing and patient selection for neoadjuvant treatment, and management of advanced and metastatic disease have been accepted as the major issues in the management of gastric cancer. The recommendations are presented with the percentage of supporting votes in the results section with related data.

Entities:  

Mesh:

Year:  2019        PMID: 30541724      PMCID: PMC6629281          DOI: 10.5152/tjg.2018.18737

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  100 in total

1.  Chemotherapy in gastric cancer: a review and updated meta-analysis.

Authors:  Karl-Gunnar Janunger; Larsolof Hafström; Bengt Glimelius
Journal:  Eur J Surg       Date:  2002

2.  Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group.

Authors:  F Bozzetti; E Marubini; G Bonfanti; R Miceli; C Piano; L Gennari
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

3.  FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features.

Authors:  K L Berger; S A Nicholson; F Dehdashti; B A Siegel
Journal:  AJR Am J Roentgenol       Date:  2000-04       Impact factor: 3.959

4.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

5.  Importance of the site of endoscopic gastric biopsy in ulcerating lesions of the stomach.

Authors:  A R Hatfield; G Slavin; A W Segal; A J Levi
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

6.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.

Authors:  H H Hartgrink; C J H van de Velde; H Putter; J J Bonenkamp; E Klein Kranenbarg; I Songun; K Welvaart; J H J M van Krieken; S Meijer; J T M Plukker; P J van Elk; H Obertop; D J Gouma; J J B van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus; M Sasako
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

7.  Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.

Authors:  J A Ajani; P F Mansfield; N Janjan; J Morris; P W Pisters; P M Lynch; B Feig; R Myerson; R Nivers; D S Cohen; L L Gunderson
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

8.  Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.

Authors:  H H Hartgrink; C J H van de Velde; H Putter; I Songun; M E T Tesselaar; E Klein Kranenbarg; J E de Vries; J A Wils; J van der Bijl; J H J M van Krieken
Journal:  Eur J Surg Oncol       Date:  2004-08       Impact factor: 4.424

Review 9.  The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.

Authors:  Patrick Schöffski
Journal:  Anticancer Drugs       Date:  2004-02       Impact factor: 2.248

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  1 in total

1.  Comment on "Dealing with the gray zones in the management of gastric cancer: The consensus statement of the İstanbul Group".

Authors:  Mustafa Hasbahçeci
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.